Apilimod mesylate by OrphAI Therapeutics for Amyotrophic Lateral Sclerosis: Likelihood of Approval

Apilimod mesylate is under clinical development by OrphAI Therapeutics and currently in Phase II for Amyotrophic Lateral Sclerosis.

Flibanserin by Sprout2 for Male Hypoactive Sexual Desire Disorder: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

November 4, 2023

Alaska’s Legislative Progress on Psychedelics for PTSD

The TDR Three Key Takeaways on Alaska and Psychedelics: Alaska’s House Bill 228 introduces a task force to explore the therapeutic use of psychedelics, marking

April 9, 2024

FDA approves Roche’s new treatment for subset of breast cancer patients

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.